IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK

ImmunityBio (IBRX) shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS), with or without papillary tumors.Acceptance of ImmunityBio’s applications seeking approval of the combo therapy by respective regulatory bodies in the EU ...